In prostate cancer patients, median pain scores for first goserelin and leuprorelin injections were below clinical significance and did not differ statistically.
In plain wordsIn prostate cancer patients, first-injection pain did not significantly differ between goserelin and leuprorelin.
- Peptide
- Goserelin
- Outcome
- No significant changeInjection pain
- Study
n = 50
- Comparator
- Leuprorelin injection (23-gauge needle; goserelin used a 16-gauge needle)
- Outcome group
- Pain · Whole body
- Studied dose
- Dose not stated
Source sentences
Median visual analogue scale pain scores for the first injections of goserelin and leuprorelin were below the level of clinical significance and were not statistically different.
1 context sentence(design, population, supporting numbers)
To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively.